Morepen Laboratories (NSE:MOREPENLAB) Cyclically Adjusted Revenue per Share: ₹30.19 (As of Mar. 2026)


NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
79 GF Score
Price ₹59.07
GF Value ₹50.13
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Morepen Laboratories Cyclically Adjusted Revenue per Share?

Morepen Laboratories NSE:MOREPENLAB -1.20% 79 Cyclically Adjusted Revenue per Share is ₹30.19 as of Mar. 2026. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 79/100 and a GF Value™ of ₹50.13 (Modestly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Morepen Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was ₹8.620. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹30.19 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Morepen Laboratories's average Cyclically Adjusted Revenue Growth Rate was 5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-05), Morepen Laboratories's current stock price is ₹59.07. Morepen Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹30.19. Morepen Laboratories's Cyclically Adjusted PS Ratio of today is 1.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Morepen Laboratories was 3.35. The lowest was 1.14. And the median was 1.80.


Morepen Laboratories  (NSE:MOREPENLAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Morepen Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=59.07/30.19
=1.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Morepen Laboratories was 3.35. The lowest was 1.14. And the median was 1.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Morepen Laboratories Cyclically Adjusted Revenue per Share Related Terms


Morepen Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Cyclically Adjusted Revenue per Share Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 28.69 30.19

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.69 29.18 29.62 30.00 30.19

NSE:MOREPENLAB vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morepen Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Morepen Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:MOREPENLAB
79GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Morepen Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=8.62/164.2724*164.2724
=8.620

Current CPI (Mar. 2026) = 164.2724.

Morepen Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201706 3.074 107.109 4.715
201709 3.379 109.021 5.091
201712 3.412 109.404 5.123
201803 3.763 109.786 5.631
201806 3.324 111.317 4.905
201809 3.990 115.142 5.693
201812 4.757 115.142 6.787
201903 4.525 118.202 6.289
201906 4.505 120.880 6.122
201909 4.705 123.175 6.275
201912 5.104 126.235 6.642
202003 4.332 124.705 5.706
202006 5.720 127.000 7.399
202009 7.429 130.118 9.379
202012 6.848 130.889 8.595
202103 6.063 131.771 7.558
202106 7.487 134.084 9.173
202109 7.618 135.847 9.212
202112 7.554 138.161 8.982
202203 6.972 138.822 8.250
202206 5.908 142.347 6.818
202209 8.411 144.661 9.551
202212 5.812 145.763 6.550
202303 7.393 146.865 8.269
202306 7.948 150.280 8.688
202309 8.334 151.492 9.037
202312 8.755 152.924 9.405
202403 8.076 153.035 8.669
202406 8.936 155.789 9.423
202409 8.165 157.882 8.495
202412 8.313 158.323 8.625
202503 8.026 157.552 8.368
202506 7.913 159.755 8.137
202509 7.552 162.289 7.644
202512 8.800 163.281 8.853
202603 8.620 164.272 8.620

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹30.19 mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Cyclically Adjusted Revenue per Share of ₹30.19 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Morepen Laboratories and its competitors.
Is Morepen Laboratories' Cyclically Adjusted Revenue per Share too high?
Morepen Laboratories' current Cyclically Adjusted Revenue per Share is ₹30.19. Overall, Morepen Laboratories has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Morepen Laboratories' Cyclically Adjusted Revenue per Share of ₹30.19 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Morepen Laboratories and its competitors. Morepen Laboratories's current Cyclically Adjusted Revenue per Share is ₹30.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹50.13, compared to a current price of ₹59.07 — trading 17.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹30.19. Morepen Laboratories' overall GF Score™ is 79/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Cyclically Adjusted Revenue per Share is ₹30.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹59.07 is trading 17.8% above its estimated GF Value™ of ₹50.13. GuruFocus considers Morepen Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:MOREPENLAB:

  • Cyclically Adjusted Revenue per Share: ₹30.19
  • GF Value™: ₹50.13 vs. price of ₹59.07 (17.8% above fair value)
  • GF Score™: 79/100 with 9 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
79GF Score

Get the complete analysis for NSE:MOREPENLAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹59.07
Price
₹50.13
GF Value